LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial
Open Access
- 16 February 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
This phase I/II study evaluated the capacity of tumor microenvironment (TME) gene engineering by intratumoral injection of a viral vector encoding a designed CD40L and 4-1BBL combined with intravenous atezolizumab (anti-PD-L1 antibody) to induce immune activation in 24 patients with stage IV malignant melanoma refractory to PD-1 inhibition. Primary objective was tolerability. Tumor response, pharmacokinetics, and biomarker evaluations were secondary. Treatment was well-tolerated in both dose cohorts (1×10 11 and 5×10 11 viral particles). Th1 immune biomarkers was increased in the TME (NanoString) as well as in blood (Olink). In long-term survivors, we observed increased markers for T cell fitness and for the immunoproteasome. The overall response rate was 17% accordingly to RECIST 1.1 and disease control was noted in 54%. Forty-six percent of patients were still alive two years post enrollment. The lower dose showed very encouraging results with a median progression-free survival of 9.7 months and median overall survival of 26.3 months (post-hoc analyses). In conclusion, TME gene engineering may have re-sensitized refractory patients to checkpoint treatment or acted alone to control tumor growth. The small sample size and single arm design limits effect interpretation but the data shows promise for continued clinical investigation. Study registration: NCT04123470.Keywords
Funding Information
- Vetenskapsrådet (2024-03471)
- Barncancerfonden (PR2021-0061)
- Cancerfonden (23 2698 Pj H)
- Lokon Pharma AB sponsored the clinical trial
This publication has 27 references indexed in Scilit:
- Lifileucel: First ApprovalMolecular Diagnosis & Therapy, 2024
- LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 studyThe Lancet Oncology, 2024
- 4-1BB immunotherapy: advances and hurdlesExperimental & Molecular Medicine, 2024
- Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibitionMolecular Therapy-Oncolytics, 2022
- CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapiesCellular & Molecular Immunology, 2021
- Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialThe Lancet Oncology, 2020
- Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40Cancer Gene Therapy, 2020
- Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironmentGene Therapy, 2016
- CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytesCancer Gene Therapy, 2014
- Distinct Effect of CD40 and TNF-Signaling on the Chemokine/Chemokine Receptor Expression and Function of the Human Monocyte-Derived Dendritic CellsCellular & Molecular Immunology, 2008